Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 9/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533750 | 0.88 | USP2 (0.31) | — | |
| SCHEMBL15647720 | 0.82 | PTGER2 (0.43) | PTGER2 | |
| SCHEMBL6516006 | 0.81 | PTGER2 (0.32) | PTGER2 | |
| SCHEMBL3458643 | 0.80 | PTGER2 (0.32) | PTGER2 | |
| SCHEMBL3458639 | 0.79 | — | — | |
| SCHEMBL3458702 | 0.78 | PTGER2 (0.46) | PTGER2 | |
| SCHEMBL533752 | 0.77 | — | — | |
| SCHEMBL3459169 | 0.76 | PTGER2 (0.41) | PTGER2 | |
| SCHEMBL533751 | 0.76 | — | — | |
| SCHEMBL533792 | 0.75 | PTGER2 (0.51) | PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | PTGER2 1/4885MMP1 1764/4885MMP9 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.